Biograph Vision Quadra™ is engineered to empower you to lead the way in clinical and translational research. With a 106 cm axial PET field of view (FoV), the scanner allows you to see a whole-body (vertex to thighs) perspective in a single bed position.
The larger perspective may help to expand precision medicine and enable you to:
- Provide new research dimensions
- Apply scientific research to create therapies and procedures that improve health outcomes
- Enable fast scanning at a low patient radiation dose
With Biograph Vision Quadra, the answers are yours to find. Experience the power of a large FoV firsthand in our clinical case gallery.
Case 1
Incredible detail in whole-body dynamic imaging.
Incredible detail in whole-body dynamic imaging.
Case 1
Incredible detail in whole-body dynamic imaging.
Incredible detail in whole-body dynamic imaging.
Case 2
Neuroendocrine tumor total body scan in 1 bed position with a 10 minute total scan time.
Neuroendocrine tumor total body scan in 1 bed position with a 10 minute total scan time.
Case 2
Neuroendocrine tumor total body scan in 1 bed position with a 10 minute total scan time.
Neuroendocrine tumor total body scan in 1 bed position with a 10 minute total scan time.
Case 3
Pediatric neuroendocrine tumor 2.0mCi in 1 bed position.
Pediatric neuroendocrine tumor 2.0mCi in 1 bed position.
Case 3
Pediatric neuroendocrine tumor 2.0mCi in 1 bed position.
Pediatric neuroendocrine tumor 2.0mCi in 1 bed position.
Case 4
18F PSMA 6.9mCi prostate cancer with lymph node metastases.
18F PSMA 6.9mCi prostate cancer with lymph node metastases.
Case 4
18F PSMA 6.9mCi prostate cancer with lymph node metastases.
18F PSMA 6.9mCi prostate cancer with lymph node metastases.
Case 5
Head & neck cancer comparing image quality from 1-minute, 2-minute, 4-minute and 10-minute whole-body scans.
Head & neck cancer comparing image quality from 1-minute, 2-minute, 4-minute and 10-minute whole-body scans.
Case 5
Head & neck cancer comparing image quality from 1-minute, 2-minute, 4-minute and 10-minute whole-body scans.
Head & neck cancer comparing image quality from 1-minute, 2-minute, 4-minute and 10-minute whole-body scans.
Case 6
Lung cancer in post-COVID-19 patient comparing image quality from 1-minute, 2-minute, 4-minute and 10-minute whole-body scans.
Lung cancer in post-COVID-19 patient comparing image quality from 1-minute, 2-minute, 4-minute and 10-minute whole-body scans.
Case 6
Lung cancer in post-COVID-19 patient comparing image quality from 1-minute, 2-minute, 4-minute and 10-minute whole-body scans.
Lung cancer in post-COVID-19 patient comparing image quality from 1-minute, 2-minute, 4-minute and 10-minute whole-body scans.
Case 7
Thyroid adenoma with axillary and mesenteric lymph node metastases.
Thyroid adenoma with axillary and mesenteric lymph node metastases.
Case 7
Thyroid adenoma with axillary and mesenteric lymph node metastases.
Thyroid adenoma with axillary and mesenteric lymph node metastases.
Case 8
18F-PSMA 6.3 mCi 10-minute whole-body scan.
18F-PSMA 6.3 mCi 10-minute whole-body scan.
Case 8
18F-PSMA 6.3 mCi 10-minute whole-body scan.
18F-PSMA 6.3 mCi 10-minute whole-body scan.
Case 9
18F-PSMA 6.7mCi 10-minute whole-body prostate cancer with lymph node and bone metastases.
18F-PSMA 6.7mCi 10-minute whole-body prostate cancer with lymph node and bone metastases.
Case 9
18F-PSMA 6.7mCi 10-minute whole-body prostate cancer with lymph node and bone metastases.
18F-PSMA 6.7mCi 10-minute whole-body prostate cancer with lymph node and bone metastases.
Case 10
18F-PSMA 6.6 mCi 10-minute whole-body recurrent prostate cancer.
18F-PSMA 6.6 mCi 10-minute whole-body recurrent prostate cancer.
Case 10
18F-PSMA 6.6 mCi 10-minute whole-body recurrent prostate cancer.
18F-PSMA 6.6 mCi 10-minute whole-body recurrent prostate cancer.
Click to download
Click to download
*Disclaimers
• Indications and usage • Important safety information • Dosage forms and strengths
Fludeoxyglucose F 18 Injection for intravenous use
Indications and usage
Fludeoxyglucose F 18 injection is indicated for positron emission tomography (PET) imaging in the following settings:
Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.
Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.
Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.
The full prescribing information is available on petnetsolutions.com.
Fludeoxyglucose F 18 Injection for intravenous use
Important safety information
Radiation Risk: Radiation-emitting products, including Fludeoxyglucose F 18 Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.
Blood Glucose Abnormalities: In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to Fludeoxyglucose F 18 Injection administration.
Adverse Reactions: Hypersensitivity reactions with pruritus, edema and rash have been reported; have emergency resuscitation equipment and personnel immediately available.
The full prescribing information is available on petnetsolutions.com.
Fludeoxyglucose F 18 Injection for intravenous use
Dosage forms and strengths
Multiple-dose 30 mL and 50 mL glass vial containing 0.74 to 7.40 GBq/mL (20 to 200 mCi/mL) of Fludeoxyglucose F 18 injection and 4.5 mg of sodium chloride with 0.1 to 0.5% w/w ethanol as a stabilizer (approximately 15 to 50 mL volume) for intravenous administration.
Fludeoxyglucose F 18 injection is manufactured by PETNET Solutions, a Siemens Healthineers Company,810 Innovation Drive, Knoxville, TN 39732.
The full prescribing information is available on petnetsolutions.com.